Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Nanoparticle-Based Antigen Delivery: Advancing Immunization Strategies against Infectious Pathogens.

Biomaterials research·2026

Same author

Intranasal mucoadhesive chitosan microspheres of ranolazine: Formulation, design, and pharmacokinetic evaluation.

Journal of pharmaceutical sciences·2026

Same author

Deep learning in image forgery: A systematic review for risk of bias (RoB).

Journal of forensic sciences·2026

Same author

Impact of thrombocytopenia on bleeding and cardiovascular outcomes in patients undergoing percutaneous coronary intervention with dual-antiplatelet therapy.

The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology·2026

Same author

Editorial: Computational intelligence for multimodal biomedical data fusion.

Frontiers in artificial intelligence·2026

Same author

Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures: The TOBRA Randomized Clinical Trial.

JAMA·2026

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Ligand based dendritic systems for tumor targeting.

Abhinav Agarwal¹, Surbhi Saraf, Abhay Asthana

¹Department of Pharmaceutical Sciences, Dr. H. S. Gour University, Sagar 470003, MP, India.

International Journal of Pharmaceutics

|December 29, 2007

Summary

This summary is machine-generated.

Dendrimers, a type of nanoparticle, can be engineered with ligands to target cancer cells specifically. This targeted drug delivery system minimizes side effects on healthy tissues, offering a promising approach for anti-cancer therapies.

More Related Videos

Ligand Nano-cluster Arrays in a Supported Lipid Bilayer

Ligand Nano-cluster Arrays in a Supported Lipid Bilayer

Published on: April 23, 2017

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Related Experiment Videos

Last Updated: Jul 8, 2026

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Ligand Nano-cluster Arrays in a Supported Lipid Bilayer

Ligand Nano-cluster Arrays in a Supported Lipid Bilayer

Published on: April 23, 2017

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Area of Science:

Nanotechnology
Oncology
Drug Delivery

Background:

Tumor cells express specific molecular signatures like transferrin and folic acid.
Conventional chemotherapy causes significant side effects due to non-specific drug distribution.

Purpose of the Study:

To review the potential of ligand-based dendritic systems for targeted anti-cancer drug delivery.
To highlight the advantages of dendrimers in reducing off-target toxicity.

Main Methods:

Utilizing dendrimers as nanosized, non-immunogenic drug carriers.
Functionalizing dendrimers with specific ligands (e.g., transferrin, folic acid) for active targeting.
Attaching anti-cancer drugs to the dendrimer platform for controlled release.

Main Results:

Dendrimers can be tailored to attach multiple ligands for enhanced tumor cell binding.
Targeted delivery via ligands reduces drug exposure to healthy tissues.
This approach offers a strategy for precise spatial distribution of bioactives.

Conclusions:

Ligand-functionalized dendrimers represent a promising platform for active targeting of anti-cancer drugs.
This targeted approach has the potential to significantly minimize adverse side effects.
Dendritic systems offer a versatile vehicle for developing next-generation cancer therapeutics.